NYSE
$122.47▼ 2.09%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $2.19BShares out 17.9M sh
Chart
Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Filings
5- 9.9Regular26.09.10 03:244Ownership#●●●
ROGERS CORP
Insider Laura Russell of Rogers Corp filed a Form 4 on September 9, 2026, reporting a change in beneficial ownership of securities effective September 5, 2026. This filing pertains to standard insider transaction reporting and does not involve any material changes to the company's capital structure or financial position.…more
$122.47-2.09%vs prev closeDetected5m · 30m · 60m · Next dayPLUSView filingShare
- 8.17After-hours26.08.18 05:224Ownership
ROGERS CORP
Rogers Corp insider Reeder Raymond Sean filed a Form 4 report on August 17, 2026, detailing changes in beneficial ownership of securities as of August 14, 2026. This filing serves as an official record of the insider's equity position adjustments.…more
$122.47-2.09%vs prev closeView filingShare - 8.12After-hours26.08.13 06:08SCHEDULE 13G/AOwnership
ROGERS CORP
According to the Schedule 13G/A filing submitted on August 12, 2026, Capital Research Global Investors has reported changes in its beneficial ownership of Rogers Corp (ROG). This filing serves as an update to the institutional investor's stake, providing shareholders with insight into the firm's current investment position.…more
$122.47-2.09%vs prev closeView filingShare
4 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report
News
GlobeNewswire- 1d agoRegular26.10.24 02:30#●●●#●●●
Roche Reports Positive Phase III Interim Data for IgA Nephropathy Drug Sefaxersen…more
Roche's investigational drug sefaxersen demonstrated a statistically significant 43.1% reduction in proteinuria compared to placebo in a phase III study for IgA nephropathy. This interim result highlights potential for disease progression control, though further evaluation of long-term kidney function is ongoing.…more
$122.47-2.09%vs prev closeDetected5m · 30m · 60m · Next dayPLUS
- 3d agoOvernight26.10.22 14:00
●●●●●●●● ●●●●● ●●●●●●
Roche announced a 7% sales increase in the third quarter, driven by strong demand for its innovative medicines and diagnostics. The company reaffirmed its full-year 2026 financial outlook, maintaining its growth momentum.…more
$122.47-2.09%vs prev close - 6d agoOvernight26.10.19 14:00
●●●●●●●● ●●●●● ●●●●●●
Roche will showcase Phase III clinical data for its lung and breast cancer drug candidates at the upcoming ESMO 2026 meeting. As this is a presentation of clinical progress rather than a regulatory approval or immediate financial catalyst, the outlook remains neutral.…more
$122.47-2.09%vs prev close
2 more news items
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report